Quarry LP’s Corvus Pharmaceuticals CRVS Stock Holding History

Quarry LP’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,653	Closed	-$26.9K	–	2227
2025 Q3	$26.9K	Buy	+3,653	New	+$18.7K	0.01%	1221

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quarry LP's CRVS Position: Q4 2025 in Review

Quarry LP sold out of Corvus Pharmaceuticals (CRVS) in Q4 2025, closing a stake of 3,653 shares — an estimated $26.9K sold.

Quarry LP first reported a position in CRVS in Q3 2025 and held it in 1 quarter. The position peaked at $26.9K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRVS as of Q4 2025.

Quarry LP reported no remaining Corvus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 3,653 Corvus Pharmaceuticals shares in Q4 2025, an estimated $26.9K.
Quarry LP first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Quarry LP's Corvus Pharmaceuticals position peaked at $26.9K in Q3 2025.
124 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.